Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02846935
Title p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Recruitment Completed
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Yogen Saunthararajah
Indications

B-cell lymphoma

lymphoma

Therapies

Decitabine + Tetrahydrouridine

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio 44195 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field